Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3630434 | 0.99 | ADORA2A (0.55) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL725880 | 0.92 | ADORA2A (0.57) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL7394674 | 0.85 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL723979 | 0.85 | ADORA2A (0.62) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5034068 | 0.85 | ADORA3 (0.59) | ADORA2AADORA2BADORA3ADORA1HIF1A | |
| SCHEMBL5040344 | 0.84 | ADORA3 (0.59) | ADORA2AADORA2BADORA3ADORA1NT5E | |
| SCHEMBL5034070 | 0.84 | ADORA3 (0.58) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL723276 | 0.84 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22567702 | 0.83 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5034544 | 0.82 | ADORA1 (0.61) | ADORA2AADORA2BADORA3ADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158208-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV Therapeutics Inc. (US) | 2010-03-03 | — | — | EP | claimed |
| WO-2008143667-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-1989214-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2007092372-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027695-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | NORTHEASTERN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2344145-A1 | COMBINATIONS OF A RATE CONTROL AGENT AND AN A-2-ALPHA RECEPTOR ANTAGONIST FOR USE IN MULTIDETECTOR COMPUTED TOMOGRAPHY METHODS | Gilead Sciences, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037122-A1 | COMBINATIONS OF A RATE CONTROL AGENT AND AN A-2-ALPHA RECEPTOR ANTAGONIST FOR USE IN MULTIDETECTOR COMPUTED TOMOGRAPHY METHODS | GILEAD PALO ALTO, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-2158208-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV Therapeutics Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2099360-A2 | MYOCARDIAL PERFUSION IMAGING | CV Therapeutics Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2066232-A1 | METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE | CV THERAPEUTICS, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2056834-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008086096-A2 | MYOCARDIAL PERFUSION IMAGING | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008042796-A2 | METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE | CV THERAPEUTICS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008028140-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007092372-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1708721-A1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005082379-A1 | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1189916-A2 | N-PYRAZOLE A 2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000078779-A2 | N-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |